Comparative Controlled Study of Analgesic, Antiasthenic and Anti-Anxiety Effects of Xenon in Patients With Parkinson's Disease

Parkinson Disease Clinical Trial

Official title:

Comparative Controlled Study of Analgesic, Antiasthenic and Anti-Anxiety Effects of Xenon in Patients With Parkinson's Disease

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04097080
• Other study ID #: NBTX-009
• Status: Recruiting
• Phase: Phase 1
• Start date: December 15, 2019
• Est. completion date: December 2021

Study information

• Verified date: March 2021
• Source: Nobilis Therapeutics Inc.
• Contact: Vlad Bogin, MD, FACP
• Phone: 971-229-1679
• Email: vlad.bogin[@]nobilistx.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study evaluates the hypothesis that the gas mixture with xenon will have a positive effect on the symptoms in patients with Parkinson's Disease. The study will test the hypothesis that the gas mixture with xenon has a symptomatic treatment potential for patients with Parkinson's Disease, as measured by change from baseline in the Unified Parkinson Disease Rating Scale (UPDRS).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: December 2021
• Est. primary completion date: November 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• The patient must be male or female over the age of 18.

• The subject must have idiopathic Parkinson's disease.

• The subject has Stage III by Hoehn and Yahr in the "on" state on a screening visit

• Subjects suffering from anxiety, depression, cognitive dysfunction

• Dopaminergic drugs should be taken in a stable dosage for 28 days prior to registration, and throughout the study

• Patients who have signed an approved consent form and are consistent with both the clinical trial plan and follow-up.

Exclusion Criteria:

• Patients have atypical parkinsonism (eg, neuroleptics, metoclopramide, flunarizin), metabolic neurodegenerative disorders (eg, Wilson's disease), encephalitis, cerebrovascular disease or degenerative disease (e.g. progressive supranuclear palsy)

• Patients who received deep brain stimulation

• Patients with cancer, HIV, kidney or liver disease.

• Patients taking new antipsychotic, antidepressant, anxiolytic or narcotic drugs for less than 3 months

Related Conditions & MeSH terms

• Parkinson Disease

Intervention

Drug:
• NBTX-001
Active drug group will receive 6 doses of NBTX-001 given three times a week.
• Standard of Care
Placebo group will receive reconstituted air given three times a week.

Locations

Country	Name	City	State
Russian Federation	Institute of Addictology	Moscow
Russian Federation	MONIKI	Moscow

Sponsors (1)

Lead Sponsor	Collaborator
Nobilis Therapeutics Inc.

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Unified Parkinson Disease Rating Scale (UPDRS)	Analysis of Unified Parkinson Disease Rating Scale (UPDRS) from baseline.The UPDRS scale refers to Unified Parkinson Disease Rating Scale, and it is a rating tool used to gauge the course of Parkinson's disease in patients. The UPDRS scale includes series of ratings for typical Parkinson's symptoms that cover all of the movement hindrances of Parkinson's disease. The UPDRS scale consists of the following five segments: 1) Mentation, Behavior, and Mood, 2) ADL, 3) Motor sections, 4) Modified Hoehn and Yahr Scale, and 5) Schwab and England ADL scale. Each answer to the scale is evaluated by a medical professional that specializes in Parkinson's disease during patient interviews. Some sections of the UPDRS scale require multiple grades assigned to each extremity with a possible maximum of 199 points. A score of 199 on the UPDRS scale represents the worst (total disability) with a score of zero representing (no disability).	Baseline to Week 24